Related references
Note: Only part of the references are listed.Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study
Sheng-Hsuan Chien et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2015)
Risk assessment of second primary cancer according to histological subtype of non-Hodgkin lymphoma
Cedric Rossi et al.
LEUKEMIA & LYMPHOMA (2015)
Trends in incidence, treatment and survival of aggressive B-cell lymphoma in the Netherlands 1989-2010
Djamila E. Issa et al.
HAEMATOLOGICA (2015)
Splenectomy and second malignancies in patients with Hodgkin lymphoma
Hilde A. M. Kooistra et al.
LEUKEMIA & LYMPHOMA (2015)
Differences in Cancer Incidence among Predominantly Muslim and Buddhist Subpopulations in Songkhla
Hutcha Sriplung et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2014)
Subsequent cancers, mortality, and causes of death in patients with mycosis fungoides and parapsoriasis: A Danish nationwide, population-based cohort study
Lise M. Lindahl et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2014)
Ibrutinib for the treatment of mantle cell lymphoma
Nimish Shah et al.
EXPERT REVIEW OF HEMATOLOGY (2014)
Sequencing an Ashkenazi reference panel supports population-targeted personal genomics and illuminates Jewish and European origins
Shai Carmi et al.
NATURE COMMUNICATIONS (2014)
Outcomes After Diagnosis of Mycosis Fungoides and Sezary Syndrome Before 30 Years of Age A Population-Based Study
Weiyun Z. Ai et al.
JAMA DERMATOLOGY (2014)
New Insights into Associated Co-morbidities in Patients with Cutaneous T-cell Lymphoma (Mycosis Fungoides)
Emmilia Hodak et al.
ACTA DERMATO-VENEREOLOGICA (2013)
The Epidemic of Non-Hodgkin Lymphoma in the United States: Disentangling the Effect of HIV, 1992-2009
Meredith S. Shiels et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2013)
Bortezomib (Velcade), Rituaimab, Cyclophosphamide, and Dexamethasone Combination Regimen Is Active as Front-Line Therapy of Low-Grade Non-Hodgkin Lymphoma
Chadi Nabhan et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2012)
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis
M. Pirani et al.
ANNALS OF ONCOLOGY (2011)
Myeloablative Doses of Yttrium-90-Ibritumomab Tiuxetan and the Risk of Secondary Myelodysplasia/Acute Myelogenous Leukemia
Anna Guidetti et al.
CANCER (2011)
Positron Emission Tomography-Computed Tomography (PET-CT) After Induction Therapy Is Highly Predictive of Patient Outcome in Follicular Lymphoma: Analysis of PET-CT in a Subset of PRIMA Trial Participants
Judith Trotman et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Risk Factors for the Development of Secondary Malignancy After High-Dose Chemotherapy and Autograft, With or Without Rituximab: A 20-Year Retrospective Follow-Up Study in Patients With Lymphoma
Corrado Tarella et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group
Michael Pfreundschuh et al.
LANCET ONCOLOGY (2011)
Variants at 6q21 implicate PRDM1 in the etiology of therapy-induced second malignancies after Hodgkin's lymphoma
Timothy Best et al.
NATURE MEDICINE (2011)
Risk-Adapted Dose-Dense Immunochemotherapy Determined by Interim FDG-PET in Advanced-Stage Diffuse Large B-Cell Lymphoma
Craig H. Moskowitz et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Second Malignancy Risks After Non-Hodgkin's Lymphoma and Chronic Lymphocytic Leukemia: Differences by Lymphoma Subtype
Lindsay M. Morton et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
SUVmax in FDG-PET at the biopsy site correlates with the proliferation potential of tumor cells in non-Hodgkin lymphoma
Reina Watanabe et al.
LEUKEMIA & LYMPHOMA (2010)
The genome-wide structure of the Jewish people
Doron M. Behar et al.
NATURE (2010)
Risk of Non-Hodgkin Lymphoma Associated with Germline Variation in Genes that Regulate the Cell Cycle, Apoptosis, and Lymphocyte Development
Lindsay M. Morton et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2009)
Etiologic heterogeneity among non-Hodgkin lymphoma subtypes
Lindsay M. Morton et al.
BLOOD (2008)
Family history of cancer as a risk factor for second malignancies after Hodgkin's lymphoma
A. Andersson et al.
BRITISH JOURNAL OF CANCER (2008)
Concussion Incidence and Time Lost from Play in the NHL During the Past Ten Years
Richard A. Wennberg et al.
CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES (2008)
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study
Stefano Sacchi et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2008)
Risk of second malignant neoplasms among lymphoma patients with a family history of cancer
Ola Landgren et al.
INTERNATIONAL JOURNAL OF CANCER (2007)
Second lymphomas and other malignant neoplasms in patients with mycosis fungoides and Sezary syndrome - Evidence from population-based and clinical cohorts
Kathie P. Huang et al.
ARCHIVES OF DERMATOLOGY (2007)
Incidence, risk factors, and pathogenesis of second malignancies in patients with non-Hodgkin lymphoma
Jonathan Tward et al.
LEUKEMIA & LYMPHOMA (2007)
Rituximab maintenance improves clinical outcome of relapsed/resistant follicular non-Hodgkin lymphoma in patients both with and without rituximab during induction: results of a prospective randomized phase 3 intergroup trial
Marinus H. J. van Oers et al.
BLOOD (2006)
Risk of second malignancy after non-Hodgkin's lymphoma: A British cohort study
NY Mudie et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Changes in cancer registry coding for lymphoma subtypes: Reliability over time and relevance for surveillance and study
CA Clarke et al.
CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2006)
Second primary malignancies after treatment for malignant lymphoma
A Okines et al.
BRITISH JOURNAL OF CANCER (2005)
Increasing incidence of late second malignancies after conditioning with cyclophosphamide and total-body irradiation and autologous bone marrow transplantation for non-Hodgkin's lymphoma
JR Brown et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Mycosis fungoides: HLA class II associations among Ashkenazi and non-Ashkenazi Jewish patients
E Hodak et al.
BRITISH JOURNAL OF DERMATOLOGY (2001)
Immunogenetics of HLA class II in Israeli Ashkenazi Jewish, Israeli non-Ashkenazi Jewish, and in Israeli Arab IDDM patients
OJ Kwon et al.
HUMAN IMMUNOLOGY (2001)
Increased risk of secondary cancers in patients with primary cutaneous T cell lymphoma
L Väkevä et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2000)
Share Paper
